CIK 0001651308
- Large accelerated filer
BeOne Medicines Ltd.
Sign in to watch- Ticker
- BEIGF
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 981209416
- Phone
- +41 616851900
- Business address
- C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, Switzerland, 4051
- Former names
- BeiGene, Ltd.
Securities
- ONC American Depositary Shares Nasdaq
- BEIGF Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $48,487,541
- in 9 filings, $47.8M under 10b5-1 plans
Net −$48,487,541. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-02-28 | Li Ji EVP and Gl. Head of Bus. Dev. | Sale | −1,749 | $143.72 | $251K | 8,251 |
| 2018-02-28 | Li Ji EVP and Gl. Head of Bus. Dev. | Sale | −1,100 | $144.78 | $159K | 7,151 |
| 2018-02-28 | Li Ji EVP and Gl. Head of Bus. Dev. | Sale | −1,400 | $145.97 | $204K | 5,751 |
| 2018-02-28 | Li Ji EVP and Gl. Head of Bus. Dev. | Sale | −1,800 | $146.92 | $264K | 3,951 |
| 2018-02-28 | Li Ji EVP and Gl. Head of Bus. Dev. | Sale | −1,551 | $148.66 | $231K | 2,400 |
| 2018-02-28 | Li Ji EVP and Gl. Head of Bus. Dev. | Sale | −2,400 | $149.49 | $359K | 0 |
| 2018-02-28 | Li Ji EVP and Gl. Head of Bus. Dev. | Exercise or conversion · Share Option (Right to Buy) | −130,000 | 2,246,000 | ||
| 2018-01-26 | Glazer Donald W. Director | Gift | −10,873 | 4,527,634 | ||
| 2018-01-18 | BAKER BROS. ADVISORS LP Director | Purchase | +335,050 | $101.00 | $33.8M | 708,025 |
| 2018-01-18 | BAKER BROS. ADVISORS LP Director | Purchase | +1,645,148 | $101.00 | $166.2M | 5,121,404 |
| 2017-12-26 | OYLER JOHN Chief Executive Officer | Sale | −8,958 | $95.55 | $856K | 110,179 |
| 2017-12-26 | OYLER JOHN Chief Executive Officer | Sale | −8,279 | $96.68 | $800K | 101,900 |
| 2017-12-26 | OYLER JOHN Chief Executive Officer | Sale | −1,700 | $97.83 | $166K | 100,200 |
| 2017-12-26 | OYLER JOHN Chief Executive Officer | Sale | −200 | $99.05 | $20K | 100,000 |
| 2017-12-26 | OYLER JOHN Chief Executive Officer | Sale | −1,000 | $100.08 | $100K | 99,000 |
| 2017-12-21 | Huang Jane CMO, Hematology | Exercise or conversion | +1,000 | $29.51 | $30K | 1,000 |
| 2017-12-21 | Huang Jane CMO, Hematology | Sale | −1,000 | $98.00 | $98K | 0 |
| 2017-12-21 | Huang Jane CMO, Hematology | Exercise or conversion · Share Option (Right to Buy) | −13,000 | 1,367,500 | ||
| 2017-12-13 | Huang Jane CMO, Hematology | Exercise or conversion | +1,500 | $29.51 | $44K | 1,500 |
| 2017-12-13 | Huang Jane CMO, Hematology | Sale | −1,300 | $94.21 | $122K | 200 |
Page 114 of 123 · 2,455 trades